Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study
Background: Detailed hemodynamic data from the phase III PATENT-1 study of riociguat in patients with pulmonary arterial hypertension (PAH) were investigated. Methods: Patients with PAH who were treatment naïve or pre-treated with endothelin receptor antagonists or non-intravenous prostanoids were...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2017]
|
| In: |
The journal of heart and lung transplantation
Year: 2017, Jahrgang: 36, Heft: 5, Pages: 509-519 |
| ISSN: | 1557-3117 |
| DOI: | 10.1016/j.healun.2016.12.012 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.healun.2016.12.012 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1053249816304727 
|
| Verfasserangaben: | Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marius M. Hoeper, Marc Humbert, Zhi-Cheng Jing, Anne M. Keogh, David Langleben, Lewis J. Rubin, Arno Fritsch, Neil Davie, and Hossein-Ardeschir Ghofrani |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575995417 | ||
| 003 | DE-627 | ||
| 005 | 20220814153357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180605s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2016.12.012 |2 doi | |
| 035 | |a (DE-627)1575995417 | ||
| 035 | |a (DE-576)505995417 | ||
| 035 | |a (DE-599)BSZ505995417 | ||
| 035 | |a (OCoLC)1341010691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Galiè, Nazzareno |e VerfasserIn |0 (DE-588)1046633201 |0 (DE-627)776778579 |0 (DE-576)399949682 |4 aut | |
| 245 | 1 | 0 | |a Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study |c Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marius M. Hoeper, Marc Humbert, Zhi-Cheng Jing, Anne M. Keogh, David Langleben, Lewis J. Rubin, Arno Fritsch, Neil Davie, and Hossein-Ardeschir Ghofrani |
| 264 | 1 | |c [2017] | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 24 December 2016 | ||
| 500 | |a Gesehen am 05.06.2018 | ||
| 520 | |a Background: Detailed hemodynamic data from the phase III PATENT-1 study of riociguat in patients with pulmonary arterial hypertension (PAH) were investigated. Methods: Patients with PAH who were treatment naïve or pre-treated with endothelin receptor antagonists or non-intravenous prostanoids were randomly assigned to riociguat up to 2.5 mg 3 times a day or placebo. Hemodynamic parameters were assessed at baseline and week 12. Results: Riociguat significantly decreased pulmonary vascular resistance in treatment-naïve (n = 221; least squares [LS] mean difference −266 dyne∙sec∙cm−5 [95% confidence interval (CI) −357 to −175; p < 0.0001]) and pre-treated (n = 222; LS mean difference −186 dyne∙sec ∙cm−5 [95% CI −252 to −120; p < 0.0001]) patients and significantly increased cardiac index (LS mean difference +0.7 [95% CI 0.5 to 0.8] and +0.5 [95% CI 0.3 to 0.7], respectively [both p < 0.0001]). Mean pulmonary artery pressure (p = 0.0056 and p = 0.0019 for treatment-naïve and pre-treated patients, respectively), mean arterial pressure (both p < 0.0001), and systemic vascular resistance (both p < 0.0001) were significantly reduced, and there was an increase in mixed venous oxygen saturation (p < 0.0001 and p = 0.0004, respectively). Results were similar in patients pre-treated with endothelin receptor antagonists and patients pre-treated with non-intravenous prostanoids. Improvements in 6-minute walking distance correlated very weakly with improvements in pulmonary vascular resistance (r = −0.21 [95% CI −0.30 to −0.11; p < 0.0001]) and cardiac index (r = 0.16 [95% CI 0.06 to 0.25; p < 0.0016]). Conclusions: Riociguat significantly improved hemodynamic parameters in pre-treated and treatment-naïve patients with PAH. | ||
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a pulmonary | |
| 650 | 4 | |a pulmonary arterial hypertension | |
| 650 | 4 | |a riociguat | |
| 650 | 4 | |a soluble guanylate cyclase stimulator | |
| 700 | 1 | |a Grünig, Ekkehard |e VerfasserIn |0 (DE-588)112535801 |0 (DE-627)618892605 |0 (DE-576)31856694X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of heart and lung transplantation |d Amsterdam [u.a.] : Elsevier Science, 1999 |g 36(2017), 5, Seite 509-519 |h Online-Ressource |w (DE-627)306659743 |w (DE-600)1500494-6 |w (DE-576)260773786 |x 1557-3117 |7 nnas |a Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study |
| 773 | 1 | 8 | |g volume:36 |g year:2017 |g number:5 |g pages:509-519 |g extent:11 |a Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healun.2016.12.012 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1053249816304727 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180605 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 112535801 |a Grünig, Ekkehard |m 112535801:Grünig, Ekkehard |d 910000 |d 950000 |d 950900 |e 910000PG112535801 |e 950000PG112535801 |e 950900PG112535801 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 3 | ||
| 999 | |a KXP-PPN1575995417 |e 3011527237 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study","title_sort":"Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study"}],"person":[{"role":"aut","family":"Galiè","display":"Galiè, Nazzareno","given":"Nazzareno"},{"family":"Grünig","display":"Grünig, Ekkehard","given":"Ekkehard","role":"aut"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"recId":"306659743","pubHistory":["Nachgewiesen 18.1999 -"],"note":["Gesehen am 15.01.20","Ungezählte Beil.: Supplement"],"disp":"Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 studyThe journal of heart and lung transplantation","part":{"extent":"11","year":"2017","issue":"5","volume":"36","text":"36(2017), 5, Seite 509-519","pages":"509-519"},"title":[{"title_sort":"journal of heart and lung transplantation","title":"The journal of heart and lung transplantation","subtitle":"a forum that includes basic science, the failing heart, and advanced lung disease ; the official publication of the International Society for Heart and Lung Transplantation"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"issn":["1557-3117"],"zdb":["1500494-6"],"eki":["306659743"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Elsevier Science","publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"[1999?]-"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1575995417"],"doi":["10.1016/j.healun.2016.12.012"]},"language":["eng"],"origin":[{"dateIssuedDisp":"[2017]","dateIssuedKey":"2017"}],"name":{"displayForm":["Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marius M. Hoeper, Marc Humbert, Zhi-Cheng Jing, Anne M. Keogh, David Langleben, Lewis J. Rubin, Arno Fritsch, Neil Davie, and Hossein-Ardeschir Ghofrani"]},"recId":"1575995417","note":["Available online 24 December 2016","Gesehen am 05.06.2018"]} | ||
| SRT | |a GALIENAZZACOMPARISON2017 | ||